Rapid Quantification of Plasma Creatinine Using a Novel Kinetic Enzymatic Assay.

limiting enzyme plasma creatinine rapid substrate kinetic assay

Journal

The journal of applied laboratory medicine
ISSN: 2576-9456
Titre abrégé: J Appl Lab Med
Pays: England
ID NLM: 101693884

Informations de publication

Date de publication:
29 04 2021
Historique:
received: 27 05 2020
accepted: 05 08 2020
pubmed: 27 11 2020
medline: 16 10 2021
entrez: 26 11 2020
Statut: ppublish

Résumé

Enzymatic assays are among the most common diagnostic tests performed in the clinical laboratory. Enzymatic substrate analysis is most commonly measured using endpoint methods; however, modulating the reaction kinetics allows fine control of the reaction rate, which can be adjusted based on specific monitoring technologies. We developed and optimized an enzymatic method for measurement of creatinine in plasma, using commonly paired enzymes of creatininase (Crtnnase), creatinase (Crtase), sarcosine oxidase (SOX), ascorbate oxidase (AOX), and horseradish peroxidase (HRP). The novel aspect of the assay is that it is fast and uses SOX as the limiting enzyme. The assay performance was assessed with respect to precision, accuracy, and interferences. The intrarun %CV (n = 12) was approximately 5% for each concentration tested, with biases ranging from -3 to -9%. The interrun %CV (n = 39) ranged from 5 to 8%, with biases ranging from -2 to -6%. During the accuracy assessment (n = 127), only 4 samples did not meet the minimum acceptability criteria. Minimal interference was observed, except at low creatinine concentrations with elevated creatine. Our novel and versatile enzymatic assay to measure plasma creatinine using kinetic analysis with SOX as the limiting enzyme is rapid (<2 mins), sensitive, and specific and demonstrates excellent concordance with the laboratory standard. We anticipate this rapid kinetic assay to be compatible with emerging technologies in the field of portable diagnostic devices, such as the usage of silicon photonics to monitor biochemical reactions.

Sections du résumé

BACKGROUND
Enzymatic assays are among the most common diagnostic tests performed in the clinical laboratory. Enzymatic substrate analysis is most commonly measured using endpoint methods; however, modulating the reaction kinetics allows fine control of the reaction rate, which can be adjusted based on specific monitoring technologies.
METHODS
We developed and optimized an enzymatic method for measurement of creatinine in plasma, using commonly paired enzymes of creatininase (Crtnnase), creatinase (Crtase), sarcosine oxidase (SOX), ascorbate oxidase (AOX), and horseradish peroxidase (HRP). The novel aspect of the assay is that it is fast and uses SOX as the limiting enzyme. The assay performance was assessed with respect to precision, accuracy, and interferences.
RESULTS
The intrarun %CV (n = 12) was approximately 5% for each concentration tested, with biases ranging from -3 to -9%. The interrun %CV (n = 39) ranged from 5 to 8%, with biases ranging from -2 to -6%. During the accuracy assessment (n = 127), only 4 samples did not meet the minimum acceptability criteria. Minimal interference was observed, except at low creatinine concentrations with elevated creatine.
CONCLUSION
Our novel and versatile enzymatic assay to measure plasma creatinine using kinetic analysis with SOX as the limiting enzyme is rapid (<2 mins), sensitive, and specific and demonstrates excellent concordance with the laboratory standard. We anticipate this rapid kinetic assay to be compatible with emerging technologies in the field of portable diagnostic devices, such as the usage of silicon photonics to monitor biochemical reactions.

Identifiants

pubmed: 33241282
pii: 6006394
doi: 10.1093/jalm/jfaa157
doi:

Substances chimiques

Creatinine AYI8EX34EU
Sarcosine Oxidase EC 1.5.3.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

688-701

Informations de copyright

© American Association for Clinical Chemistry 2020. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Angela M Jimenez Valencia (AM)

Laboratory for Integrated Nanodiagnostics, Johns Hopkins University School of Medicine, Baltimore, MD.
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.

Lindsay A Kryszak (LA)

Laboratory for Integrated Nanodiagnostics, Johns Hopkins University School of Medicine, Baltimore, MD.
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.

Joshua Goheen (J)

Laboratory for Integrated Nanodiagnostics, Johns Hopkins University School of Medicine, Baltimore, MD.
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.

Willem Van Roy (W)

IMEC, Leuven, Belgium.

Gabrielle Woronoff (G)

IMEC, Leuven, Belgium.

Evelien Mathieu (E)

Laboratory for Integrated Nanodiagnostics, Johns Hopkins University School of Medicine, Baltimore, MD.

Hildur Gudjonsdottir (H)

Laboratory for Integrated Nanodiagnostics, Johns Hopkins University School of Medicine, Baltimore, MD.

Tim Stakenborg (T)

IMEC, Leuven, Belgium.

William A Clarke (WA)

Laboratory for Integrated Nanodiagnostics, Johns Hopkins University School of Medicine, Baltimore, MD.
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH